{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-209988","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2021-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.524396+00:00","generated_at":"2026-06-30T06:55:24.443100+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tempest Therapeutics appoints Christine Pellizzari to board, enters new exec employment agreements","bullets":["Appointed Christine Pellizzari as Class II Director, serving on Audit Committee; term expires 2023.","CEO Stephen Brady gets $475,283 base salary, 40% target bonus, 250k stock options, and severance of 12–18 months salary plus bonus.","President Thomas Dubensky gets $476,283 base, 40% target bonus, 250k options; severance of 12–18 months salary plus bonus.","CMO Samuel Whiting gets $400k base, 35% target bonus; severance of 9–12 months salary plus bonus.","All directors and executive officers entered indemnification agreements with the Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-209988","json":"https://secwatch.observer/filing/0001193125-21-209988.json","markdown":"https://secwatch.observer/filing/0001193125-21-209988.md","text":"https://secwatch.observer/filing/0001193125-21-209988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312521209988/0001193125-21-209988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312521209988/d69289d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T06:55:24.443100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5437d1e5f7","claim":"Christine Pellizzari was appointed as Class II Director at Tempest Therapeutics, Inc..","evidence_excerpt":"On July 1, 2021, the Board appointed Christine Pellizzari as a Class II Director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312521209988/0001193125-21-209988-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}